BriaCell Therapeutics (NASDAQ:BCTX) Price Target Cut to $15.00

BriaCell Therapeutics (NASDAQ:BCTX) had its price target trimmed by HC Wainwright from $18.00 to $15.00 in a research note published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.

BriaCell Therapeutics Stock Performance

BriaCell Therapeutics stock opened at $0.60 on Thursday. The stock has a market cap of $11.01 million, a PE ratio of -0.48 and a beta of 1.31. BriaCell Therapeutics has a one year low of $0.46 and a one year high of $6.36. The stock has a fifty day moving average of $0.71 and a 200 day moving average of $1.55.

Institutional Trading of BriaCell Therapeutics

An institutional investor recently raised its position in BriaCell Therapeutics stock. Onyx Bridge Wealth Group LLC grew its stake in BriaCell Therapeutics Corp. (NASDAQ:BCTX) by 66.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 50,000 shares of the company’s stock after buying an additional 20,000 shares during the quarter. Onyx Bridge Wealth Group LLC owned approximately 0.31% of BriaCell Therapeutics worth $143,000 as of its most recent SEC filing. 15.42% of the stock is owned by hedge funds and other institutional investors.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers.